Prosecution Insights
Last updated: November 04, 2026

Hyloris Developments S A

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Hyloris Developments S A currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit. VALENROD, YEVGENY is the busiest examiner, holding 1 pending office action. With only 1 pending office action, the prosecution profile is currently limited to a single point of contact at the patent office. This concentration means that the company's immediate success in this technology area is tied to the examination of this one matter.

The involvement of 1 distinct art unit and 1 distinct examiner indicates a highly focused prosecution path. Practitioners should analyze the historical allowance rates of VALENROD, YEVGENY to better understand the likely trajectory of the 1 pending office action. Because there are no other pending matters, the portfolio lacks the diversification that comes with having actions spread across multiple examiners. The current strategy must be tailored specifically to the requirements of the single art unit and examiner involved in this Biotechnology & Pharmaceuticals filing.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
VALENROD, YEVGENY 1 72.6% +25.0%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18610343 METHOD OF INITIATING OR ESCALATING DOFETILIDE DOSE AND FORMULATIONS THEREFOR VALENROD, YEVGENY —

Top Art Units

Art UnitApps
1628 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18610343 METHOD OF INITIATING OR ESCALATING DOFETILIDE DOSE AND FORMULATIONS THEREFOR VALENROD, YEVGENY 1628 §103§112DP Non-Final OA — Pending Mar 20, 2024

Managing Hyloris Developments S A's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Hyloris Developments S A have?

Hyloris Developments S A has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Hyloris Developments S A applications?

Yevgeny Valenrod has the most, with 1 of Hyloris Developments S A's pending office actions.

What technology area are Hyloris Developments S A's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month